Metabolomycs

Metabolomycs is a Southern California biotechnology company focused on the clinical application of next-generation metabolomics and targeted mass spectrometry for human disease detection and characterization. The company uses biochemical signatures and its MetaSync Analysis platform to identify "inborn-like errors of metabolism" and other metabolic abnormalities associated with disease. Its published and presented work has centered on blood-based metabolic signatures for early detection, prognosis, and risk stratification in pancreatic, ovarian, and breast cancers, as well as treatment-response assessment in gynecologic malignancies. Rather than developing therapeutics, Metabolomycs appears to operate as a diagnostics and translational metabolomics company serving research, clinical, and partnership opportunities.